Takeda Development Center Americas Inc. — Sponsor Intelligence | 66 EU Trials

Filter these 66 trials by condition, phase, country and more.

Open in Search →

66 Registered trials

27 Recruiting

35 Completed trials

25 Countries active

59 Unique IMPs

100% Results reported

Phase III

Phase II

Phase III: 36 Phase II/III: 2 Phase II: 18 Phase I/II: 1 Phase III/IV: 1 Phase IV: 2 Phase I (Other): 4 Phase I (FiH): 2

Oversight events:

2 serious breaches 10 temporary halts across 7 trials

View oversight register →

100%

35 of 35 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Narcolepsy 5 Crohn's disease 4 Lennox-Gastaut syndrome 3 Myelodysplastic syndrome 3 Psoriatic arthropathy 3 Alpha-1 anti-trypsin deficiency 2 Colitis ulcerative 2 IgA nephropathy 2 Primary immunodeficiency syndrome 2 Crohn´s disease 2 Myelofibrosis 1 Psoriasis 1

Top IMPs

ZASOCITINIB 13 VEDOLIZUMAB 8 ELRITERCEPT 4 N-{(2S,3R)-4,4-DIFLUORO-1-(2-HYDROXY-2-METHYLPROPANOYL)-2-[(2,3',5'-TRIFLUORO[1,1'-BIPHENYL]-3-YL)METHYL]PYRROLIDIN-3-YL}ETHANESULFONAMIDE 4 FAZIRSIRAN 3 HUMAN NORMAL IMMUNOGLOBULIN 3 HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN RECOMBINANT) 3 MEZAGITAMAB 3 SOTICLESTAT 3 ALLOGENEIC ADIPOSE TISSUE-DERIVED MESENCHYMAL STEM CELLS EXPANDED 2 APREMILAST 2 APREMILAST, APREMILAST 2

All trials

66 total

Study to Investigate the Efficacy, Safety, and Tolerability of Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infe… Pending

2024-518420-80-00 Phase III 12 countries HUMAN NORMAL IMMUNOGLOBULIN; TECLISTAMAB
A Phase 3, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib in Subjects with Active Pso… Pending

2025-522586-30-00 Phase III 13 countries ZASOCITINIB
A randomized double blind placebo controlled study of TAK-360 for the treatment of narcolepy with cataplexy Pending

2025-522587-33-00 Phase II 1 country N-{(6R)-7,7-DIFLUORO-2-[5-FLUORO-4-(2,4,6-TRIFLUOROPHENYL)-1,2-BENZOXAZOL-3-YL]-…
A Phase 2 trial to assess efficacy and safety of zasocitinib in moderate to severe hidradenitis suppurativa Pending

2025-522831-33-00 Phase II 4 countries ZASOCITINIB
Vedolizumab Subcutaneous Long-term Open-label Extension Study in Pediatric Subjects Recruiting

2023-508804-39-00 Phase III 10 countries VEDOLIZUMAB
Long-term Safety and Tolerability of TAK-881 in Subjects with Primary Immunodeficiency Diseases (PIDD) Recruiting

2023-505946-24-00 Phase III 8 countries HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN RECOMBINANT)
Phase 3 Study of Vedolizumab Subcutaneous in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease Recruiting

2023-503188-40-00 Phase III 10 countries VEDOLIZUMAB
A preventive study of bleeding episodes for children with severe von Willebrand disease (VWD). Recruiting

2023-509877-22-00 Phase III 4 countries OCTOCOG ALFA; VONICOG ALFA
Efficacy and Safety of Vedolizumab Intravenous in Pediatric Chronic Pouchitis Recruiting

2023-504773-20-00 Phase III 8 countries VEDOLIZUMAB
Phase 3 Trial of TAK-330 for Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation Recruiting

2022-503012-16-00 Phase III 11 countries HUMAN COAGULATION FACTOR IX, PROTEIN C, HUMAN COAGULATION FACTOR VII, HUMAN COAG…
A phase 3 trial comparing elritercept versus epoetin alfa for treatment of anemia due to lower-risk MDS in ESA-naïve adults who require RBC … Recruiting

2025-523544-12-00 Phase III 14 countries ELRITERCEPT
A Phase 3 Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less… Recruiting

2025-522567-15-00 Phase III 4 countries ZASOCITINIB
Zasocitinib in Nonsegmental Vitiligo Recruiting

2025-522309-40-00 Phase II 4 countries ZASOCITINIB
A Follow-up Study of Mezagitamab in Adults with Chronic Primary Immune Thrombocytopenia Recruiting

2025-521692-31-00 Phase III 12 countries MEZAGITAMAB
A Study of Mezagitamab in Adults With Primary IgA Nephropathy Kidney Condition Recruiting

2025-520825-19-00 Phase III 12 countries MEZAGITAMAB
A Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Na… Recruiting

2024-517711-70-01 Phase II 3 countries
A Study to Evaluate the Efficacy and Safety of Mezagitamab Subcutaneous Injection Compared With Placebo in Adults With Chronic Immune Thromb… Recruiting

2024-514401-54-00 Phase III 12 countries MEZAGITAMAB
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn’s Disease (CD) Recruiting

2024-518914-18-00 Phase II 14 countries ZASOCITINIB
A Study of Zasocitinib in Adults with Psoriatic Arthritis Who Have Not Taken Biologic Medicines Recruiting

2024-513111-27-00 Phase III 12 countries APREMILAST, APREMILAST; ZASOCITINIB
A Phase 3, Single-Arm, Multiple-Dose, Pharmacokinetic Comparability Trial Between TAK-881 and HYQVIA in Adults With Chronic Inflammatory Dem… Recruiting

2024-517450-95-00 Phase III 8 countries HUMAN NORMAL IMMUNOGLOBULIN; HUMAN NORMAL IMMUNOGLOBULIN, HYALURONIDASE (HUMAN R…
A Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects with Active Psoriatic Arthritis Stratified by Prior… Recruiting

2024-513112-99-00 Phase III 4 countries ZASOCITINIB
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Phase III/IV 18 countries UPADACITINIB; VEDOLIZUMAB
A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with IH Recruiting

2024-517712-29-00 Phase II 3 countries
A study of elritercept to treat transfusion-dependent anemia due to very low, low, or intermediate risk myelodysplastic syndromes Recruiting

2024-516009-22-00 Phase III 11 countries ELRITERCEPT

Showing 1–24 of 66 trials

← All sponsors A–Z